Xinyue Health 002 162: The invested artificial reproduction projects mainly include the cooperation projects of Yichun Maternal and Child Health Hospital in Jiangxi and Nikko Artificial Reproduction Center in the United States, which are all in normal operation. Jindawei 002626: Now it has developed into a new star in the manufacturing of health care products and sports nutrition products.
Sunflower Pharmaceutical Co., Ltd. 002737: The company is a large-scale brand pharmaceutical enterprise group focusing on the production of Chinese patent medicines, supplemented by chemical medicines, biological medicines and health care products, and integrating drug research and development, manufacturing and marketing. The company is rich in variety resources, the product echelon construction is perfect, and efforts are made to enlarge the core varieties and create a gold single product group.
Dong 'e Ejiao 000423: The company's tenth five-year new product development plan: drug direction (Ejiao classic prescription, Ejiao blood-enriching, Ejiao lung-moistening, etc. ), health care products and functional foods (Ejiao nourishing the heart, beautifying and anti-aging, regulating menstruation and preparing for pregnancy, improving immunity, etc. At present, there is no plan to launch new products such as Ejiao drinks.
Livzon Group 0005 13: Potential leader of respiratory and inhalation preparations. Its main products include Shenqi Fuzheng injection, Livzon Dele (dipotassium citrate) series products, antiviral particle HIV antibody diagnostic reagents and so on. The company's western medicine pharmacy, raw material medicine and health care products business grew steadily.
Sihuan Bio 005 18: The company is a listed pharmaceutical company integrating R&D, production and sales.
Fosun Pharma (600 196): The company is mainly engaged in health care unit.
Angel Yeast: In 2020, the company achieved a total revenue of 8.933 billion, a year-on-year increase of 65,438+06.73%. The management of the company indicated that the target of 202 1 annual continuous income10 billion yuan remained unchanged. It is estimated that in 20021year, the domestic yeast revenue is expected to maintain the growth range of high single and low double, the growth rate of yeast extracts and health products is about 20%, and the overseas market revenue is expected to increase 15%-20%.
Pien Tze Huang: In 2020, the company achieved a total revenue of 65 1 1 billion, a year-on-year increase of 65.438+03.78%. It is a first-class protected Chinese medicine certified by the state and has the right to use musk, a scarce raw material. It is a leading enterprise of traditional Chinese medicine for liver diseases in China, and its brand value ranks first in the Hurun Report. The company has three core competitiveness: strong brand, controlling raw materials and expanding channels, and its performance continues to grow steadily.
Wang Yichuang: The 2020 annual report shows that the company's operating income is 65.438+29.9 billion yuan, up -654.38+00.49% year-on-year, and the compound growth rate in recent three years is 654.38+03.24%. The company will realize the explosive capacity of products, incubate its own brand of food and health care products, and create a second growth curve. It is expected that the valuation can be digested by the rapid growth of performance. Q3 predicts that the company's high growth will continue, which is a scarce target for cosmetics to maintain high growth in the off-season.